Development and Oral Bioavailability of Self-Emulsifying Formulation of Ketoconazole

DOI:

https://doi.org/10.37285/ijpsn.2012.5.4.5

Authors

  • Arundhati Bhattacharyya
  • M Bajpai

Abstract

Ketoconazole is an imidazole antifungal drug belonging to the class II of Biopharmaceutic Classification System. Maintenance of gastric acidity is essential for adequate dissolution and absorption of ketoconazole. Concurrent administration of antacid and antiulcer preparations decreases the oral absorption of ketoconazole often causing therapeutic failure.  The aim of this study was to evaluate whether a self-emulsifying formulation of ketoconazole would be able to overcome the pH dependent dissolution and oral bioavailability. Self-emulsifying drug delivery system (SEDDS) was prepared after selecting the oil, surfactant and co-surfactant by solubility analysis. Optimum ratio of the components was finalized on the basis of drug content, self-emulsification and mean droplet diameter. The effect of pH on dissolution was studied in comparison to the pure drug. Oral bioavailability was determined in comparison to aqueous suspension in rats and the effect of co-administration of ranitidine hydrochloride solution and a commercially available liquid antacid preparation was studied. The optimized formulation containing 20% Capryol 90 and 40% each of Carbitol and Tween 80, exhibited 100% drug release regardless of the pH whereas the pure drug exhibited a highly pH dependent dissolution. The AUC0-24 resulted with oral administration of the SEDDS formulation was about 34%, 43% and 60% higher compared to the aqueous suspension when administered alone, administered with ranitidine and administered with antacid respectively. The results of the present study demonstrate that self-emulsifying formulations can be utilized for oral delivery of weakly basic drugs like ketoconazole which exhibit pH dependent dissolution.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

SEDDS, Ketoconazole, Dissolution, Oral bioavailability, Gastric pH, Antacids

Downloads

Published

2013-02-28

How to Cite

1.
Bhattacharyya A, Bajpai M. Development and Oral Bioavailability of Self-Emulsifying Formulation of Ketoconazole. Scopus Indexed [Internet]. 2013 Feb. 28 [cited 2024 Dec. 22];5(4):1858-65. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/594

Issue

Section

Research Articles

References

Arida AI, Al-tabakha MM and Hamoury HAJ (2007). Improving the high variable bioavailability of griseofulvin by SEDDS. Chem Pharm Bull 55: 1713-1719.

Elder EJ, Evans JC, Scherzer BD, Hitt JE, Kupperblatt GB, Saghir SA and Markham DA (2007). Preparation, characterization, and scale-up of ketoconazole with enhanced dissolution and bioavailability. Drug Dev Ind Pharm 33: 755-765.

Gursoy RN and Benita S (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomedicine and Pharmacotherapy 58: 173-182.

Heo MY, Piao ZZ, Kim TW, Cao QR, Kim A and Lee BJ (2005). Effect of solubilizing and microemulsifying excipients in polyethylene glycol 6000 solid dispersion on enhanced dissolution and bioavailability of ketoconazole. Arch Pharm Res 28: 604-611.

Hong JY, Kim JK, Song YK, Park JS and Kim CK (2006). A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Contr Rel 110: 332-8.

Huang Y, Colaizzi JL, Bierman RH, Woestenborghs R and Heykants J (1986). Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 30: 206-10.

Kanaujia P, Lau G, Ng WK, Widjaja E, Hanefeld A, Fischbach M, Maio M and Tan RB (2011). Nanoparticle formation and growth during in vitro dissolution of ketoconazole solid dispersion. J Pharm Sci 100: 2876-2885.

Kommuru TR, Gurley B, Khan MA and Reddy IK (2001). Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm 12: 233-246.

Lake-Bakaar G, Tom W, Lake-Bakaar D, Gupta N, Beidas S, Elsakr M and Straus E (1988). Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 109: 471-473.

Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H and Schentag JJ (1991). Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 35: 1765–1771.

Rasenack N and Müller BW (2002). Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res 19: 1894-1900.

Skiba M, Skiba-Lahiani M, Marchais H, Duclos R and Arnaud P (2000). Stability assessment of ketoconazole in aqueous formulations. Int J Pharm 198:1–6.

Sweetman SC (2009). Martindale: The Complete Drug Reference, 36th Ed. Vol-1. Pharmaceutical Press, London, pp 539-540.

Van Der Meer JW, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J and Brugmans J (1980). The influence of gastric acidity on the bio-availability of ketoconazole. J Antimicrob Chemother 6: 552-554.

Woo JS, Song YK, Hong JY, Lim SJ and Kim CK (2008). Reduced food-effect and enhanced bioavailability of a self-micro-emulsifying formulation of itraconazole in healthy volunteers. Eur J Pharm Sci 33: 159-165.

Zhou R, Moench P, Heran C, Lu X, Mathias N, Faria TN, Wall DA, Hussain MA, Smith RL and Sun D (2005). pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model. Pharm Res 22: 188-192.